



EXXO SKIN is a next-generation regenerative exosome formulation engineered to optimize dermal repair and cellular communication. Utilizing bioactive extracellular vesicles combined with Lactobacillus-derived postbiotic complexes, it helps modulate inflammatory pathways (including NF-κB signaling), reinforce epidermal barrier integrity, and restore cutaneous homeostasis following aesthetic procedures.
The formulation is enriched with high-purity adipose-derived stem cell conditioned media and PDRN (polydeoxyribonucleotide), supporting fibroblast proliferation, collagen type I synthesis, angiogenesis, and extracellular matrix remodeling. By enhancing cellular turnover and accelerating tissue recovery, EXXO SKIN is strategically positioned for anti-aging protocols, post-energy device recovery, barrier-compromised skin, and regenerative combination treatments.

Through its multi-pathway regenerative approach, EXXO SKIN enhances dermal-epidermal cross-talk and supports growth factor–mediated signaling, including pathways associated with TGF-β and VEGF regulation. This contributes to improved microvascular support, optimized nutrient diffusion, and more efficient extracellular matrix organization. The presence of structural matrix-associated proteins such as laminin, fibronectin, and hyaluronan further supports cellular adhesion, hydration balance, and tissue architecture stabilization. By addressing both inflammatory modulation and structural regeneration, EXXO SKIN provides aesthetic professionals with a biologically driven solution designed for predictable integration into advanced clinical protocols.










EXXO HAIR supports follicular longevity by influencing cellular energy metabolism and oxidative stress regulation within the scalp microenvironment. Through exosome-mediated signaling, it helps attenuate inflammatory mediators associated with follicular miniaturization and promotes a balanced cytokine profile conducive to sustained anagen maintenance. By reinforcing extracellular matrix integrity around the follicular unit and enhancing microvascular dynamics, EXXO HAIR contributes to improved shaft thickness, structural anchoring, and overall scalp resilience, making it suitable for structured, protocol-based hair restoration programs in advanced aesthetic practice.
EXXO HAIR is a regenerative exosome formulation engineered to influence key molecular pathways governing follicular cycling, particularly the Wnt/β-catenin signaling pathway, a central regulator of hair follicle stem cell activation and anagen initiation. By delivering bioactive extracellular vesicles containing growth factors, peptides, and regulatory microRNAs, EXXO HAIR supports the stabilization of β-catenin within dermal papilla cells, promoting transcription of genes associated with follicular proliferation and differentiation.
Through modulation of perifollicular inflammation and enhancement of dermal papilla–epithelial cross-talk, the formulation helps create a pro-anagen microenvironment. The inclusion of adipose-derived stem cell conditioned media and PDRN further supports angiogenesis, fibroblast activation, and extracellular matrix remodeling — optimizing oxygenation and nutrient delivery to the follicular unit.
By targeting both signaling activation and microenvironment correction, EXXO HAIR is positioned as a biologically driven protocol for androgenetic alopecia, telogen effluvium, and early-stage follicular miniaturization, particularly in combination with microneedling, PRP, or energy-based scalp therapies.

This unique formulation combines hydrating, regenerating, and protective ingredients to create a versatile and effective skincare solution for anti-aging, brightening, and moisturizing. Revitalize your skin with advanced hydration and repair, powered by over 2% PDRN.








KGMP stands for Korea Good Manufacturing Practice. It is a set of regulations and guidelines established by the Ministry of Food and Drug Safety (MFDS) in South Korea to ensure that medical devices and pharmaceuticals are consistently produced and controlled according to quality standards. The main objectives of KGMP are to safeguard public health by ensuring that products are safe, effective, and of high quality.
Key aspects of KGMP include:
– Quality Management: Establishing a quality management system to oversee all aspects of production and control.
– Facility Requirements: Ensuring that manufacturing facilities meet specific standards for cleanliness, organization, and equipment.
– Documentation: Maintaining detailed records of all manufacturing processes, quality controls, and batch production.
– Process Control: Implementing rigorous controls and monitoring throughout the production process to prevent errors and ensure consistency.
– Personnel Training: Ensuring that all personnel involved in manufacturing are properly trained and qualified.
Compliance with KGMP is mandatory for manufacturers wishing to market their medical devices and pharmaceuticals in South Korea. It aligns with international standards like ISO 13485, ensuring that products meet both domestic and global quality requirements.
The Food and Drug Administration (FDA) is a U.S. federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, food supply, cosmetics, and products that emit radiation. The FDA also plays a crucial role in regulating the manufacturing, marketing, and distribution of these products to ensure they meet established standards. Additionally, the FDA oversees tobacco products and enforces regulations to reduce tobacco-related health issues. Through its comprehensive oversight and regulatory activities, the FDA aims to promote and protect the health and well-being of the American public.
CE 1370 refers to a specific type of CE marking used in the European Union to indicate that a product complies with the essential health, safety, and environmental protection requirements set out in the relevant EU directives and regulations. The “1370” is the identification number of the notified body that has assessed the product’s conformity.
In the context of medical devices, for example, CE 1370 signifies that the product has been evaluated by a notified body (identified by the number 1370) and has met the required standards. This marking allows the product to be legally marketed and sold within the European Economic Area (EEA).
The CE marking is crucial for market access and consumer safety, ensuring that products meet high standards and can be traced back to their manufacturers.
ISO 13485 is an internationally recognized standard for quality management systems specifically designed for the medical device industry. It outlines the requirements for a comprehensive quality management system that ensures the consistent design, development, production, installation, and delivery of medical devices that are safe and effective for their intended purpose.
Key aspects of ISO 13485 include:
– Quality Management System (QMS) Requirements: Establishing a robust QMS tailored to the medical device industry.
– Risk Management: Implementing risk management processes throughout the product lifecycle.
– Regulatory Compliance: Ensuring compliance with regulatory requirements relevant to medical devices.
– Product Realization: Covering all stages from design and development to production and servicing.
– Continual Improvement: Promoting continual improvement of the QMS and processes to enhance product quality and safety.
ISO 13485 helps organizations meet regulatory requirements and improve overall product quality and reliability, thereby enhancing customer satisfaction and trust in their medical devices.